Mavezelimab

玛维泽利单抗

Report date: 2024/12/18 10:43:35

Base Information

Drug NameMavezelimab
Drug Alias NameFavezelimab费维泽利单抗MK-4280
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionLymphocyte activation gene 3 protein inhibitors
TargetsLymphocyte activation gene 3 protein
Therapy Area/IndicationsNeoplasm MetastasisSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[25] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme LLC
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell +[6] 
Inactive IndicationsNeoplasm Metastasis

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG